SEATTLE CHILDREN’S HOSPITAL (DBA SEATTLE CHILDREN’S RESEARCH INSTITUTE)
发明人:
Jensen, Michael
申请号：
NZ73945015
公开号：
NZ739450A
申请日:
2015.04.08
申请国别(地区):
NZ
年份:
2019
代理人:
摘要：
Aspects of the invention described herein, concern approaches to make genetically modified T-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize CD4+ and/or CD8+ T-cells from a mixed T-cell population, such as peripheral blood or apheresis derived mononuclear cells. The CD4+ and/or CD8+ T-cells are activated, genetically modified, and propagated in separate or isolated cultures with one or more cytokines, which support survival, engraftment and/or proliferation as well as promoting or inducing the retention of cell surface receptors such as CD62L, CD28, and/or CD27. Preferably, such cytokines may be IL2, IL7, IL21, or IL15. The CAR may be specific for CD19. Included herein are also methods of treatment, inhibition, amelioration or elimination of a cancer, particularly leukaemia, by administering one or more types of the genetically engineered T-cells to a subject.
